Amerigroup
District of Columbia

Provider update

Precertification update for Truvada (emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide)

Effective January 6, 2020, precertification clinical criteria will change for the following medications when indicated for pre-exposure prophylaxis (PrEP):

- Truvada® (emtricitabine/tenofovir disoproxil fumarate)
- Descovy® (emtricitabine/tenofovir alafenamide)

When indicated for PrEP, Truvada and Descovy are subject to precertification. Requests for Truvada or Descovy may be approved when all the following criteria are met:

- Appropriate indication/population for PrEP:
  - Truvada: indicated for PrEP to reduce the risk of sexually acquired HIV-1 in adults at high risk[1]
  - Descovy: indicated in at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of HIV-1 infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex[2]
- Attestation for all of the following labs:[1, 2]
  - Negative HIV status
  - Baseline renal function
  - Baseline bone density measurement

This change applies to Amerigroup District of Columbia, Inc. members enrolled in the District of Columbia Healthy Families Program, Alliance and the Immigrant Children's Program.

Our *Preferred Drug List* and searchable formulary are located on the provider website at https://providers.amerigroup.com/DC > Provider Resources & Documents > Pharmacy.

If you have questions about this communication, please contact your Provider Relations Representative or call Provider Services at 1-800-454-3730.

1 Gilead Sciences, Inc. Truvada (emtricitabine/tenofovir disoproxil fumerate) package insert. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021752s047lbl.pdf. Revised March 2016. Accessed Nov. 18, 2019.
2 Gilead Sciences, Inc. Descovy (emtricitabine/tenofovir alafenamide) package insert. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208215s000lbl.pdf. Revised April 2016. Accessed Nov. 18, 2019.